This report provides an overview of a horizon scanning project that was undertaken on behalf of the Accelerated Access Collaborative (AAC) and its partners (NHSE/I, ABPI, MHRA, NICE Catapult) that aimed to gather intelligence on ATMPs to help plan for the introduction of these into the NHS. The scan provided the core dataset on ATMPs in the clinical development pipeline with a potential product licence/launch in the NHS, up until ~2026. It complements the enhanced ATMP horizon scan undertaken by NHSE/I Commercial Directorate by providing a spine of information which will be worked up into Therapeutic Product Profiles when technologies are closer to being adopted in the NHS (0-3years).
Horizon Scan for Advanced Therapy Medicinal Products
Advanced Therapy Medicinal Products (ATMPs) are novel therapies based on cells, genes or tissues with the potential to address the underlying cause of the diseases. ATMPs come with potentially significant implementation challenges, high costs and regulatory & assessment uncertainties.